ERK5-IN-1

An ERK5 inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1625.00

1300.00

- +
10mg

￥2287.00

1830.00

- +
50mg

￥6687.00

5350.00

- +
100mg

￥9500.00

7600.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

XMD8-85 is an ERK5 inhibitor (IC₅₀ = 87 nM in an enzyme assay).¹ It is selective for ERK5 over tyrosine non-receptor kinase 2 (TNK2; IC₅₀ = 959 nM), but does inhibit the leucine-rich repeat kinase 2 (LRRK2) mutant LRRK2^G2019S (IC₅₀ = 26 nM), which has been found in patients with Parkinson’s disease.^2,1 XMD8-85 inhibits EGF-induced ERK5 autophosphorylation in HeLa cells (EC₅₀ = 0.19 μM).¹

1.Deng, X., Elkins, J.M., Zhang, J., et al.Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-onesEur. J. Med. Chem.70758-767(2013) 2.Groendyke, B.J., Powell, C.E., Feru, F., et al.Benzopyrimidodiazepinone inhibitors of TNK2Bioorg. Med. Chem. Lett.30(4)126948(2020)

Protocol

Kinase experiment:

Kinase activity is determined in an assay volume of 40 μL in kinase buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 1 mM 2-mercaptoethanol) containing 200 ng of pure active ERK5 and the indicated amount of inhibitor. Reaction started by adding 10 mM magnesium acetate, and 50 μM [γ-32P]-ATP (500 cpm/pmol) and 250 μM PIMtide (ARKKRRHPSGPPTA) as substrates. Assays are carried out for 20 min at 30°C, terminated by applying the reaction mixture onto p81 paper and the incorporated radioactivity measured[1].

参考文献:

[1]. Deng X, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem. 2013;70:758-767.